Igm compositions and methods of mucosal delivery of these compositions

Patent metadata

Field	Value
Publication number	US-2022017453-A2
Application number	US-201917052671-A
Country	US
Kind code	A2
Filing date	May 6, 2019
Priority date	Aug 7, 2013
Publication date	Jan 20, 2022
Grant date	—

Abstract

Described herein are methods of inducing an immune response directed towards preventing or reducing the risk of a human immunodeficiency virus (HIV) infection in a mammalian subject. The subject is administered an effective amount of a composition containing IgM antibodies directed to an epitope of an envelope protein of the HIV virus. Also disclosed here are vaccine compositions comprising IgM antibodies directed to one or more epitopes of one or more human immunodeficiency virus envelope proteins. Also disclosed are recombinant immunoglobulin M compositions containing a Fcγ fragment of an immunoglobulin G.

First claim

What is claimed is:

1 . A method of inducing an immune response directed towards preventing or reducing the risk of a human immunodeficiency virus (HIV) infection in a mammalian subject, comprising
administering to the mammalian subject an effective amount of a composition containing immunoglobulin M (IgM) antibodies directed to an epitope of a human immunodeficiency virus envelope protein.

2 . The method of claim 1 , wherein the composition containing IgM antibodies is formulated for a mucosal administration.

3 . The method of claim 2 , wherein the mucosal layer is a rectal mucosal layer.

4 . The method of claim 1 , wherein the human immunodeficiency virus envelope protein is HIV-1 gp120.

5 . A recombinant immunoglobulin M composition, comprising:
a Fcγ fragment of an immunoglobulin G connected to a carboxy terminus of a joining chain of an immunoglobulin M.

6 . The recombinant immunoglobulin M composition of claim 5 , wherein the Fcγ fragment of the immunoglobulin G is connected to the carboxy terminus of the joining chain of the immunoglobulin M via a linker.

7 . The recombinant immunoglobulin M composition of claim 6 , wherein the linker is a glycine- and serine-rich linker.

8 . A recombinant immunoglobulin M composition, comprising:
a Fcγ fragment of an immunoglobulin G connected to a carboxy terminus of a constant region of a light chain of immunoglobulin M.

9 . The recombinant immunoglobulin M composition of claim 8 , wherein the Fcγ fragment of the immunoglobulin G is connected to the carboxy terminus of the constant region of the light chain of the immunoglobulin M via a linker.

10 . The recombinant immunoglobulin M composition of claim 9 , wherein the linker is a glycine- and serine-rich linker.

11 . A recombinant immunoglobulin M composition, comprising:
a plurality of monomers of a bispecific antibody containing:
a first constant region linked to a first variable region, wherein the first variable region includes a variable region of a first heavy chain and a variable region of a first light chain capable of specifically binding to a first epitope of a pathogen; and
a second constant region linked to a second variable region, wherein the second variable region includes a variable region of a second heavy chain and a variable region of a second light chain capable of specifically binding to a second epitope of the pathogen.

12 . The recombinant immunoglobulin M composition of claim 11 , wherein the first epitope and the second epitopes are two different epitopes of a human immunodeficiency virus envelope protein.

13 . The recombinant immunoglobulin M composition of claim 11 , wherein the first epitope is from a first human immunodeficiency virus envelope protein and the second epitope is from a second human immunodeficiency virus envelope protein.

14 . The recombinant immunoglobulin M composition of claim 12 , wherein the first epitope is an epitope of a human immunodeficiency virus envelope protein gp120.

15 . The recombinant immunoglobulin M composition of claim 12 , wherein the first epitope is a carbohydrate dependent epitope related to the V3 loop of the human immunodeficiency virus envelope protein gp120.

16 . The recombinant immunoglobulin M composition of claim 12 , wherein the second epitope is a part of a V2 loop of the human immunodeficiency virus envelope protein gp120.

17 . The recombinant immunoglobulin M composition of claim 12 , wherein the second epitope is a part of a CD4 binding site of the human immunodeficiency virus envelope protein gp120.

18 . The recombinant immunoglobulin M composition of claim 11 , wherein the variable region of the first light chain is connected to the variable region of the first heavy chain, which is connected to the first constant region.

19 . The recombinant immunoglobulin M composition of claim 11 , wherein the variable region of the second light chain is connected to the variable region of the second heavy chain, which is connected to the second constant region.

20 . The recombinant immunoglobulin M composition of claim 11 , wherein the first constant region is linked to the first variable region of the first heavy chain via a first glycine- and serine-rich linker and the second constant region is linked to the second variable region of the second heavy chain via a second glycine- and serine-rich linker.

21 . The recombinant immunoglobulin M composition of claim 11 , further comprising a joining chain connecting the first constant region of a heavy chain of a first monomer to a third constant region of a heavy chain of a second adjacent monomer to form a pentameric immunoglobulin M composition.

Assignees

• Univ Louisiana At Lafayette

Inventors

• Ruprecht Ruth
• Gong Siqi

Classifications

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07C211/48

  N-alkylated amines · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61P31/18

  for HIV · CPC title